Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 6, 2024

Consolidated Financial Summary for the First Six Months of the Fiscal Year Ending March 31, 2025 (Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559 (URL: https://www.zeria.co.jp/english/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to submit the Semi-annual Securities Report: November 8, 2024
Scheduled date to commence dividend payments: December 2, 2024
Preparation of supplementary documents to the financial results: Yes
Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2024 through September 30, 2024)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2024	42,422	15.7	6,459	21.2	7,949	44.6	6,061	12.3
September 30, 2023	36,678	8.8	5,327	(9.6)	5,495	6.1	5,396	35.0

Note: Comprehensive income: For the six months ended September 30, 2024: 9,709 million yen [(13.7)%]
For the six months ended September 30, 2023: 11,254 million yen [39.5%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2024	137.51	–
September 30, 2023	122.43	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
September 30, 2024	158,339	88,567	55.7
March 31, 2024	150,533	79,828	52.9

Reference: Equity: As of September 30, 2024: 88,268 million yen As of March 31, 2024: 79,622 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2024	–	22.00	–	22.00	44.00
Year ending March 31, 2025	–	23.00			
Year ending March 31, 2025 (Forecast)			–	23.00	46.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2025 (April 1, 2024 through March 31, 2025)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	86,000	13.6	11,000	14.3	11,000	29.2	8,500	9.9	192.83

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None
Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the semi-annual consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)
1) Number of shares issued as of the end of the term (including treasury shares):
As of September 30, 2024: 53,119,190 shares As of March 31, 2024: 53,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of September 30, 2024: 9,039,651 shares As of March 31, 2024: 9,039,354 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2024: 44,079,667 shares
For the six months ended September 30, 2023: 44,080,153 shares

* Semi-annual financial summary is exempt from review conducted by certified public accountants or an audit corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.